Wealth Quarterback LLC Purchases 3,795 Shares of Novo Nordisk A/S $NVO

Wealth Quarterback LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 23.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,816 shares of the company’s stock after buying an additional 3,795 shares during the period. Wealth Quarterback LLC’s holdings in Novo Nordisk A/S were worth $1,368,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth approximately $30,000. NewSquare Capital LLC raised its stake in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Disciplina Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Dagco Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $37,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $49.21 on Wednesday. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $112.52. The stock has a fifty day moving average of $54.96 and a 200 day moving average of $61.30. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market capitalization of $219.72 billion, a price-to-earnings ratio of 13.52, a P/E/G ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

NVO has been the subject of several analyst reports. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Jefferies Financial Group began coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $59.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.